Quidel Corp (QDEL) Tops Q1 EPS by 24c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Quidel Reports First Quarter 2020 Financial Results
May 6, 2020 4:10 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2020.
First Quarter 2020 Highlights
Total revenue increased 18% to $174.7 million, from $148.0 million in the first quarter of 2019. Cardiometabolic Immunoassay revenue decreased 18% to $53.9 million, and decreased 17% on a constant currency basis. Molecular Diagnostic Solutions revenue grew 45% from the first quarter of 2019 to $8.4 million. Influenza revenue increased 69% to $79.6 million, compared with $47.2 million in the... More